Navigation Links
InterMune to Release Third Quarter Financial Results on October 28
Date:10/21/2010

BRISBANE, Calif., Oct. 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will release third quarter 2010 financial results on Thursday, October 28, 2010 at 4:00 p.m. Eastern time.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 20132776.  To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.  

A replay of the webcast and teleconference will be available approximately three hours after the call.  The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 20132776.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes pirfenidone for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY).  A Marketing Authorization Application (MAA) for pirfenidone is under review by the European Medicines Agency (EMA).  The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) announced ... be released on Thursday, August 13, 2015, before the ... management will host a conference call to discuss the ... release outlining the financial results and business update will ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference ...
(Date:7/29/2015)... ... July 29, 2015 , ... Finding gooey or crusty ... quite normal. Although there are a considerable number of terms in popular use to ... post-sleep material is a mixture of mucus, blood cells, skin cells and dust, but ...
(Date:7/29/2015)... ... July 29, 2015 , ... Asymmetrex, LLC founder ... evaluating the full range of capabilities of its unique cache of technologies for ... the day-to-day renewal and repair of normal tissues and organs. This property makes ...
(Date:7/28/2015)... Nev. , July 28, 2015  PDL BioPharma, ... today announced that the Company will release its second ... 30, 2015, on Wednesday, August 5, 2015, after market ... webcast that day at 4:30 p.m. Eastern Time to ... the call will be available via the webcast link ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2
... Mass., July 23 NxStage Medical,Inc. (Nasdaq: ... today announced ongoing public access to current summary,information ... end-stage,renal-disease (ESRD) who undergo hemodialysis at home on ... to the conventional regimen of therapy,received three times ...
... WILMINGTON, Del., July 23 More than a ... AZN ) to inquire about the,company,s prescription savings ... pharmacists, according to a year-long survey of more ... percent of the patients who called,AstraZeneca,s information center ...
... Future, CAMBRIDGE, Mass., July 23 Genzyme Corporation,(Nasdaq: ... growth in the second,quarter, along with significant progress in ... to approximately $1.171 billion from,$933.4 million in last year,s ... areas of the business., GAAP net income was ...
Cached Biology Technology:NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 2NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 3NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 4NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 5AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 2AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 3Genzyme Reports Strong Second-Quarter Growth 2Genzyme Reports Strong Second-Quarter Growth 3Genzyme Reports Strong Second-Quarter Growth 4Genzyme Reports Strong Second-Quarter Growth 5Genzyme Reports Strong Second-Quarter Growth 6Genzyme Reports Strong Second-Quarter Growth 7Genzyme Reports Strong Second-Quarter Growth 8Genzyme Reports Strong Second-Quarter Growth 9Genzyme Reports Strong Second-Quarter Growth 10Genzyme Reports Strong Second-Quarter Growth 11Genzyme Reports Strong Second-Quarter Growth 12Genzyme Reports Strong Second-Quarter Growth 13Genzyme Reports Strong Second-Quarter Growth 14Genzyme Reports Strong Second-Quarter Growth 15Genzyme Reports Strong Second-Quarter Growth 16Genzyme Reports Strong Second-Quarter Growth 17
(Date:7/8/2015)... -- The consumer products industry for innovative tech ... such as wearables, smart wallets & other smart technology are ... continues to rapidly grow.  Biometrics & Wearable Device Companies in ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ... GPRO ) and Baidu Inc. (NASDAQ: BIDU ) ...
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... Georgia Institute of Technology have developed a strategy to ... prevent the pollutant from finding its way from a ... a zero emission car, and a transportation system completely ... dioxide emissions from large-scale sources such as power plants ...
... developing is a goal of Raphael Kopan, Ph.D., professor ... School of Medicine. The moss plant (Physcomitrella patens) ... Spencer T. Olin Professor and chair of the WUSTL ... toward that goal. Heres how. The gene ...
... in the media, and recently, in our daily lives, ... is affecting global climate change. Studying just how carbon ... one Northwestern University professor is doing his part by ... associate professor of civil and environmental engineering in the ...
Cached Biology News:Carbon capture strategy could lead to emission-free cars 2Carbon capture strategy could lead to emission-free cars 3Carbon capture strategy could lead to emission-free cars 4Moss protein plays role in Alzheimer's disease 2Moss protein plays role in Alzheimer's disease 3Moss protein plays role in Alzheimer's disease 4Studying rivers for clues to global carbon cycle 2Studying rivers for clues to global carbon cycle 3
... for Alkaline Phosphatase conjugates. The product ... both the enzyme and the antibody following ... product has been chemically engineered to increase ... shelf life, resistance to various shipping conditions ...
AC input: 50-60 Hz230 V...
... Microarray Slide features an ultra-thin nitrocellulose ... is the first protein microarray slide ... nitrocellulose in a thin film with ... ,The PATH™ Slide can be ...
AC input: 50-60 Hz 115-120 V...
Biology Products: